Work

Rapid Achievement of MR4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal

Year: 2015

Type: article

Source: Blood

DOI: 10.1182/blood.v126.23.4050.4050

Authors: Ellen K. Ritchie, Rosalind Catchatourian, Rebecca B. Klisovic, Michael W Deininger, Harry P. Erba, Jerald P. Radich, Michael R. Savona, Ghulam Warsi, Carole S. Paley, Ilva Dautaj, Felice P. Lin, Michael J. Mauro

Institutions: Weill Cornell Medicine, Cook County Health and Hospitals System, The Ohio State University, University of Utah, University of Alabama at Birmingham, Fred Hutch Cancer Center, Vanderbilt University Medical Center, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4230188273

FWCI: 0.454

Cites:

Cited by: 3

Related to: 10